Guardant Health Stock Surges on Bernstein Price Target Hike
Bernstein SocGen Group raised its price target on Guardant Health to $200 from $175, maintaining an Outperform rating. The upgrade came after positive news about the company's colon cancer blood test, boosting investor sentiment.
Key Numbers
Guardant Health (GH) shares surged after Bernstein SocGen Group raised its price target on the cancer-screening company to $200 per share, up from $175. The firm also maintained its Outperform rating.
Rating Change
- New Price Target: $200
- Previous Price Target: $175
- Rating: Outperform (maintained)
- Increase: $25 (approximately 14%)
Analyst Rationale
Bernstein analysts believe Guardant Health is well-positioned to capitalize on growing demand for non-invasive cancer screenings, particularly after positive data from its colon cancer blood test. They argue the market has not fully priced in the potential of this test, leaving room for upside.
Context
The price target hike came less than a day after Guardant Health announced new data for its colon cancer blood test. The stock had experienced volatility previously, but the upgrade provided a fresh catalyst. Other analysts have yet to comment on the development.
What to Make of It
The raised price target reflects analyst confidence in Guardant Health's growth prospects, especially as its products advance through development and regulatory approval. However, investors should monitor clinical trial results and regulatory decisions before making investment decisions.
Frequently Asked Questions
Found this useful? Share it